局部晚期甲状腺癌患者应用阿帕替尼的效果及安全性研究

Study on the efficacy and safety of apatinib in patients with locally advanced thyroid cancer

目的 探讨局部晚期甲状腺癌患者应用阿帕替尼的效果及安全性。方法 选取2019年3月~2021年3月我院局部晚期甲状腺癌患者30例,依据简单随机数字表法分为研究组(n=15)与对照组(n=15)。对照组采取125I粒子植入治疗,研究组在对照组基础上采取阿帕替尼;统计两组肿瘤控制率、治疗前后血管内皮生长因子(VEGF)及甲状腺球蛋白(Tg)水平、不良反应发生率。结果 研究组肿瘤控制率(93.33%)高于对照组(80.00%),但组间比较无显著差异(P>0.05);治疗前两组血清VEGF及Tg水平间无显著差异(P>0.05),治疗后两组血清VEGF及Tg水平较治疗前降低,且研究组低于对照组(P<0.05);研究组消化道反应、高血压、手足综合征、皮肤损伤、咽喉炎发生率与对照组间无显著差异(P>0.05)。结论 常规干预基础上采取阿帕替尼对局部晚期甲状腺癌患者进行治疗,可在一定程度上提升肿瘤控制率,可能与调节VEGF与Tg的表达水平具有关联性,且该方案不会增加不良反应发生风险,安全性具有保证。

Objective To investigate the efficacy and safety of apatinib in patients with locally advanced thyroid cancer. Methods Thirty patients with locally advanced thyroid cancer in our hospital from March 2019 to March 2021 were selected and divided into a study group(n=15) and a control group(n=15) according to a simple random number table method.The control group was treated with 125I seed implantation, and the study group was treated with apatinib on the basis of the control group. The tumor control rate, the levels of vascular endothelial growth factor(VEGF) and thyroglobulin(TG) before and after treatment and the incidence of adverse reactions were counted. Results The tumor control rate in the study group(93.33%) was higher than that in the control group(80.00%), but there was no significant difference between the groups(P > 0.05).There was no significant difference in the levels of serum VEGF and TG between the two groups before treatment(P > 0.05). After treatment, the levels of serum VEGF and TG in the study group were lower than those in the control group(P < 0.05).There was no significant difference in the incidence of gastrointestinal reaction, hypertension, hand foot syndrome, skin injury and pharyngitis between the study group and the control group(P > 0.05). Conclusion On the basis of routine intervention, the treatment of patients with locally advanced thyroid cancer with apatinib can improve the tumor control rate to a certain extent, which may be related to the regulation of the expression levels of VEGF and TG, and the scheme will not increase the risk of adverse reactions, and the safety is guaranteed.